Cross-Sector entity
gene-therapy is the sole category represented across all 1 tracked stories. Dextenza is most often covered alongside DaVita, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Dextenza appears in 1 tracked Cross-Sector story from June 22, 2026.
1 verified story tracked
Last mentioned: Jun 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 1 tracked stories. Dextenza is most often covered alongside DaVita, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Dextenza appears in 1 tracked Cross-Sector story from June 22, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dextenza. Shared-story counts are live from our verified record — not editorial picks.
Ocular Therapeutix's commercial revenues are shrinking amid massive losses, while Prime Medicine's Prime Editing platform promises a DNA cure but lacks any product revenue. Both illustrate the extreme risk-reward calculus of biotech investing, where a single clinical win can eclipse years of cash burn.
Source: Pamela Kock (us) · Pamela Kock (us)
